AstraZeneca PLC (LON:AZN)

Market Cap	209.68B
Revenue (ttm)	43.24B
Net Income (ttm)	6.99B
Shares Out	1.55B
EPS (ttm)	4.48
PE Ratio	30.20
Forward PE	18.22
Dividend	2.45 (1.76%)
Ex-Dividend Date	Aug 7, 2025

Volume	3,045,769
Average Volume	1,991,468
Open	13,786
Previous Close	13,890
Day's Range	13,268 - 13,786
52-Week Range	9,574 - 15,474
Beta	0.19
RSI	42.68
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: London Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD